1365267-37-3 Usage
Uses
1. Used in Pharmaceutical Synthesis:
Benzoic acid, 2-[[[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]aMino]carbonyl]is used as an intermediate in the synthesis of Bis-[Des(5-Chloro-2-carboxythienyl)] Rivaroxaban Phthalamide (B415135), which is an impurity of Rivaroxaban (R538000). Rivaroxaban is a highly potent and selective, direct FXa inhibitor, making it an essential compound in the development of antithrombotic medications.
2. Used in Antithrombotic Applications:
In the pharmaceutical industry, Benzoic acid, 2-[[[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]aMino]carbonyl]contributes to the development of antithrombotic agents, such as Rivaroxaban. These agents are crucial in the prevention and treatment of blood clot-related conditions, including deep vein thrombosis, pulmonary embolism, and stroke.
3. Used in Research and Development:
Benzoic acid, 2-[[[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]aMino]carbonyl]also plays a significant role in research and development within the pharmaceutical sector. It is utilized in the study of the chemical properties and interactions of various compounds, as well as in the development of new drugs and therapies targeting blood clotting disorders and related conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1365267-37-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,5,2,6 and 7 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1365267-37:
(9*1)+(8*3)+(7*6)+(6*5)+(5*2)+(4*6)+(3*7)+(2*3)+(1*7)=173
173 % 10 = 3
So 1365267-37-3 is a valid CAS Registry Number.
1365267-37-3Relevant academic research and scientific papers
PROCESS FOR DETERMINING THE SUITABILITY FOR DISTRIBUTION OF A BATCH OF A THIOPHENE-2-CARBOXAMIDE DERIVATIVE
-
Page/Page column 33, (2012/04/04)
The present invention relates to a process for determining the suitability for distribution of a batch of rivaroxaban or of a pharmaceutical composition thereof. In particular, it also relates to two impurities of rivaroxaban, to their use as reference markers to determine the purity of a sample of rivaroxaban or a composition thereof, to analytical methods for determining the purity of a sample of rivaroxaban or a composition thereof and to a process of preparing rivaroxaban or pharmaceutical compositions thereof which are free or substantially free of such impurities.
